The concentrations of the proinflammatory IL-12, IL-18, and IL-23 were not significantly different in COVID-19 patients compared to healthy controls, or between COVID-19 patients before and after one-week therapy (Figure 1). This evidence concerns the gene IL18 and COVID-19.